Companies › Shaanxi Micot Pharmaceutical Technology
3 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Genitourinary, Other, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MT1013 Calcimimetic agent (allosteric modulator of calcium-sensing receptor) | CASR | Phase 3 | Secondary Hyperparathyroidism, Chronic Kidney Disease; Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Nov 2026 |
| MT200605 TrkB (NTRK2) receptor agonist | NTRK2 | Phase 2 | Acute Ischemic Stroke | – |
| MT1011 Factor IIa and Factor Xa inhibitor reversal agent | F2, F10 | Phase 1 | Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06976177 | MT1013 | Phase 2 | Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Genitourinary | Aug 2025 |
| NCT07024160 | MT1011 | Phase 1 | Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation | Other | Apr 2026 |
| NCT07205328 | MT200605 | Phase 2 | Acute Ischemic Stroke | Neurology | Jun 2026 |
| NCT07122401 | MT1013 | Phase 3 | Secondary Hyperparathyroidism, Chronic Kidney Disease | Genitourinary | Nov 2026 |
Bayer Roche Amgen Calcilytix Therapeutics, Inc., a BridgeBio company CSL Behring Takeda VarmX Xuanzhu Biopharmaceutical Dompé Farmaceutici Nuvation Bio
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) H. Lundbeck Shanghai Bao Pharmaceuticals Akebia Therapeutics Leadiant Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.